This pharmaceutical company, which focuses on small molecule tumor drug therapy, successfully listed on the market!

In recent years, in terms of oncology drugs, pharmaceutical companies that choose to develop large-molecule biologic drugs have competed, and small-molecule drugs have a relatively good competition pattern, and they have also shown great potential in the treatment of tumors and non-tumor diseases
.
According to Frost & Sullivan’s data, China’s small molecule tumor targeted therapy market is expected to reach 120.
5 billion yuan by 2025, with a compound annual growth rate of 26.
3% from 2020 to 2025, and it is expected to increase by 2030.
To 207 billion yuan, the compound annual growth rate from 2025 to 2030 is 11.
4%
.
In recent years, with the expansion of medical insurance coverage and the increasing ability of residents to pay, the field of small molecule drugs has also attracted a number of pharmaceutical companies to actively deploy
.
At the same time, capital has also increased in this field
.
On October 15 news, Heyu-B, which focuses on the discovery and development of innovative and differentiated small molecule tumor therapies, was officially listed on the Hong Kong Stock Exchange with an issue price of HK$12.
46 per share and a market value of HK$8.
753 billion
.
Heyu-B is a domestic new drug research and development company, focusing on the research and development of new tumor drugs, focusing on small molecule tumor targeting and tumor immunity drugs, and developing first-in-class or best-in-class of novel and high-potential drug targets Innovative drugs
.
The prospectus shows that Heyu’s product pipeline mainly covers small-molecule tumor precision therapy and small-molecule tumor immunotherapy.
There are 14 drug candidates, 5 of which are in the clinical stage.
Up to now, the company has been established in 4 countries and regions around the world.
Obtained 9 IND approvals
.
In addition, Heyu-B has a fibroblast growth factor receptor (FGFR) pipeline, and its core products include FGFR4 inhibitor ABSK011 and pan-FGFR inhibitor ABSK091
.
Among them, ABSK011 is a potential highly selective small molecule FGFR4 inhibitor, which is being developed for the treatment of advanced hepatocellular carcinoma (hepatocellular carcinoma) activated by abnormal FGFR4 signaling pathway.

.
At present, the company has initiated phase Ib clinical trials for advanced solid tumors in Taiwan, and has submitted ABSK011 combined with Roche’s antibody PD-L1 antibody atezolizumab for the treatment of patients with advanced liver cancer cells.
Roche will provide A Tecilizumab
.
Currently, there is no FGFR4 inhibitor on the market globally
.
ABSK091 is a potentially highly selective small-molecule pan-FGFR inhibitor, which is being developed for the treatment of various solid tumors and is introduced with authorization from AstraZeneca
.
As of press date, only 3 pan-FGFR inhibitors have been approved in the world, and there are no approved pan-FGFR inhibitors in China
.
Some analysts believe that Heyu's ABSK091 is expected to achieve corner overtaking and has the potential to become the best-in-class drug among the global pan-FGFR inhibitors
.
The data shows that the FGFR4 inhibitor market is expanding
.
Sullivan predicts that the global FGFR4 inhibitor market will reach US$2.
435 billion from US$232 million from 2025 to 2030, with a compound annual growth rate of 60.
1%.
The global FGFR4 inhibitor market will expand rapidly
.
The pan-FGFR inhibitors are still in the preliminary development stage.
In 2020, the world will be about 100 million U.
S.
dollars, and Sullivan expects to increase to 21.
5 billion U.
S.
dollars in 2035
.
Judging from the layout of Heyu-B in this field, it can be seen that its vision is unique
.
Based on its rich product development pipeline, Heyu-B's listing has won the favor of many domestic and foreign capitals, including LAV, UBS, BlackRock, Warburg Pincus, Temasek, OrbiMed, Vivo, Hudson Bay, Lake Bleu Prime, Janchor Partners, Cornerstone investors such as AIHC
.
At the same time, its joint sponsors are Morgan Stanley and JP Morgan Chase, which shows that Heyu-B has been highly recognized
.
According to the prospectus, the net proceeds from Heyu Pharmaceutical’s IPO will be used for the following purposes: about 19.
7% for the clinical development and future R&D and commercialization of the core candidate product ABSK011; about 32.
6% for the core candidate product ABSK091 (AZD4547) Clinical development and future research and development, commercialization, etc.
; about 28.
0% are used in the company's other clinical stage products and pipeline candidates; about 8.
4% are used in pre-clinical research, including continuous development of R&D platforms and research and development of new pre-clinical Candidate drugs
.